Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Mol Psychiatry. 2013 Sep 3;19(7):801–810. doi: 10.1038/mp.2013.104

Figure 3. Smoking cessation with transdermal nicotine, by study and NRG3 rs1896506 genotype. A).

Figure 3

Eight-week quit rate was significantly lower in A/* carriers of the rs1896506 genotype in both the discovery cohort and the replication cohort. B) Six-month quit rate in the pooled sample of participants from both cohorts who received standard 8-week duration therapy was significantly lower in A/* carriers of the rs1896506 genotype. The number of subjects in each group is indicated above its respective bar.